Finanzen von National Research Corp (NRC)NRCNational Research Corp

Evaluating the bottom line, NRC Health maintains a gross margin of 56.41%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -9.15%, while the net margin is -9.28%. These profitability ratios, combined with a Return on Equity (ROE) of 39.82%, provide a clear picture of how effectively NRC converts its operational activities into shareholder value.

In the context of the broader market, NRC competes directly with industry leaders such as ASTH and DGX. With a market capitalization of $449.69M, it holds a significant position in the sector. When comparing efficiency, NRC's gross margin of 56.41% stands against ASTH's 9.10% and DGX's 32.53%. Such benchmarking helps identify whether NRC Health is trading at a premium or discount relative to its financial performance.

NRC has shown a significant year-over-year increase in total recurring contract value (TRCV) of 11% in Q2 2026, reaching $151.9 million. However, net income has been inconsistent, with a notable loss of -$328,300 in Q2 2026, which raises concerns about profitability.